𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

✍ Scribed by William K. Oh; Miah-Hiang Tay; Jiaoti Huang

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
153 KB
Volume
109
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Amplification of the androgen receptor g
Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer
✍ Koivisto, Pasi A.; Rantala, Immo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 2 views

p53 protein expression of 30 hormone-refractory locally recurrent prostate cancers was compared with their matched untreated primary tumour specimens. In addition, androgen receptor (AR) gene amplification and p53 protein immunostaining were compared. p53 positivity increased during hormonal therapy

A phase 3 randomized controlled trial of
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro

A Phase II study of estramustine, doceta
A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813
✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,